Tegafur,Gimeracil and Oteracil Potassium

Generic Name: Tegafur,Gimeracil and Oteracil Potassium

Brand Names: -

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Indication: 用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Phase 2

Terminated

Conditions: Resected Pancreatic Cancer
Adjuvant Chemotherapy
Pancreatic Cancer

Interventions: Drug: S-1

First Posted Date: 2019-08-28

Last Posted Date: 2021-12-06

Lead Sponsor: TTY Biopharm

Target Recruit Count: 36

Registration Number: NCT04070313

Locations: 🇨🇳
Chang Gung Memorial Hospital_Linkou, Linkou, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

and more 1 locations

A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Phase 2

Conditions: Gastric Cancer
Neoadjuvant Therapy

Interventions: Radiation: SIB-IMRT
Drug: S-1
Drug: SOX
Procedure: Surgery

First Posted Date: 2019-08-20

Last Posted Date: 2022-01-24

Lead Sponsor: Jing Jin, M.D.

Target Recruit Count: 82

Registration Number: NCT04062058

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Neoplasms

Interventions: Drug: Pemetrexed
Drug: S-1
Drug: Bevacizumab

First Posted Date: 2019-02-18

Last Posted Date: 2022-07-25

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Registration Number: NCT03843853

Locations: 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )

Phase 2

Conditions: Pancreatic Cancer

Interventions: Drug: Albumin-bound paclitaxel
Drug: S-1
Drug: Oxaliplatin
Drug: Gemcitabine

First Posted Date: 2019-01-31

Last Posted Date: 2019-01-31

Lead Sponsor: Yanqiao Zhang

Target Recruit Count: 30

Registration Number: NCT03825328

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2

Conditions: Gastric Cancer With Positive Exfoliative Cancer Cells

Interventions: Drug: apatinib
Drug: paclitaxel
Drug: S-1

First Posted Date: 2018-10-24

Last Posted Date: 2018-10-31

Lead Sponsor: Hebei Medical University

Target Recruit Count: 36

Registration Number: NCT03718624

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Phase 3

Withdrawn

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: S-1
Drug: Bevacizumab
Drug: Capecitabine

First Posted Date: 2018-10-17

Last Posted Date: 2021-03-08

Lead Sponsor: Fujian Cancer Hospital

Registration Number: NCT03708536

Locations: 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China

S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: S-1

First Posted Date: 2018-09-12

Last Posted Date: 2021-02-11

Lead Sponsor: Fudan University

Target Recruit Count: 133

Registration Number: NCT03668366

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Phase 2

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Apatinib
Drug: S-1

First Posted Date: 2018-09-07

Last Posted Date: 2018-09-19

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 30

Registration Number: NCT03662035

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Phase 3

Active, not recruiting

Conditions: Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Placebo
Biological: Pembrolizumab
Drug: Cisplatin
Drug: 5-FU
Drug: Oxaliplatin
Drug: Capecitabine
Drug: S-1
Biological: Trastuzumab

First Posted Date: 2018-08-03

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 738

Registration Number: NCT03615326

Locations: 🇪🇸
Hospital Universitario Central de Asturias ( Site 1402), Oviedo, Asturias, Spain
🇺🇸
Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025), Philadelphia, Pennsylvania, United States
🇺🇸
University of Rochester ( Site 0041), Rochester, New York, United States

and more 189 locations

The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer Stage IIIB
Gastric Cancer Stage IIIC

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Other: TCM
Drug: S-1
Drug: Docetaxel
Drug: 5-FU

First Posted Date: 2018-07-31

Last Posted Date: 2023-12-18

Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Target Recruit Count: 270

Registration Number: NCT03607656

Locations: 🇨🇳
Longhua Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy